AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification.

Sowalsky, Adam G; Sharp, Adam; Trostel, Shana Y; de Bono, Johann S; Plymate, Stephen R

Sowalsky, Adam G; Sharp, Adam; Trostel, Shana Y; de Bono, Johann S; Plymate, Stephen R.

Afiliação

Sowalsky AG; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, MD, United States. Electronic address: adam.sowalsky@nih.gov.
Sharp A; The Institute of Cancer Research, London, United Kingdom; The Royal Marsden, London, United Kingdom.
Trostel SY; Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, MD, United States.
de Bono JS; The Institute of Cancer Research, London, United Kingdom; The Royal Marsden, London, United Kingdom.
Plymate SR; Department of Medicine, University of Washington, Seattle, WA, United States; Puget Sound VA Health Care System, Geriatric Research Education and Clinical Center, Seattle, WA, United States.

Cancer Treat Res Commun ; 28: 100218, 2021.

Article em En | MEDLINE | ID: mdl-33516656

Assuntos

Neoplasias de Próstata Resistentes à Castração; Biomarcadores; Humanos; Estudos Longitudinais; Masculino; Feniltioidantoína

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Observational_studies Limite: Humans / Male Idioma: En Revista: Cancer Treat Res Commun Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google